Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03212521 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT03212521 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 230 participants.
The verdict
NCT03212521, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.
Interventions
- DRUG Glecaprevir/Pibrentasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03212521
The ClinicalTrials.gov registry entry for NCT03212521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir/Pibrentasvir is the first listed.
NCT03212521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03212521 about?
NCT03212521 is a clinical study titled "Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1". A study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.
What is the current status of trial NCT03212521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2017-08-07. Estimated completion is 2018-08-13.
What interventions are being tested in trial NCT03212521?
The interventions under investigation include: Glecaprevir/Pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT03212521?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.